Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis

Arthritis and Rheumatism

Volumn 43, Issue 11, 2000, Pages 2606-2608

  Bloom, Bradley J ^a  

^a HASBRO CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNITY; CASE REPORT; DRUG EFFECT; FEMALE; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; PRIORITY JOURNAL; SCHOOL CHILD;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, JUVENILE RHEUMATOID; CHILD, PRESCHOOL; DIABETES MELLITUS; FEMALE; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS;

EID: 0033763545     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200011)43:11<2606::AID-ANR31>3.0.CO;2-X     Document Type: Article

References (9)

1. Etanercept in children with polyarticular juvenile rheumatoid arthritis
2. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
3. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial
4. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial
5. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis
6. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease
7. Juvenile rheumatoid arthritis in children with diabetes mellitus
8. Increased in vivo production of tumor necrosis factor after development of diabetes in non-treated, long-term diabetic BB rats
9. Intravenous immunoglobulin therapy in systemic-onset juvenile rheumatoid arthritis: A follow-up study